Grade 3/4 mucositis was more frequent in patients treated with CCRT-VIPD (66.7%) than CHOP-like regimens (6.3%), asparaginase-based regimens (32.3%) and others anti-MDR drug regimens (20.0%), p < 0.001 (Table 3). The gene discussed is ASPG; the disease is mucositis.